Episodes

  • #14: Citius Oncology's LYMPHIR™ Launch Strategy

    #14: Citius Oncology's LYMPHIR™ Launch Strategy
    Jan 10 2025
    Citius Oncology is preparing to launch LYMPHIR™, a novel treatment for cutaneous T-cell lymphoma (CTCL), and is simultaneously exploring strategic options to maximize its market impact. These options include partnerships and acquisitions to bolster its position within the $400 million CTCL market. The company is focusing on a targeted launch strategy that includes patient support programs and securing international licensing agreements. Their aim is to provide patients with a much-needed therapy while increasing shareholder value. This launch follows years of development and regulatory hurdles.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    3 mins
  • #13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment

    #13 : Rybrevant & Lazcluze: A New Era in Lung Cancer Treatment
    Jan 10 2025
    Johnson & Johnson's Rybrevant and Lazcluze drug combination shows significant improvement in overall survival for patients with EGFR-mutated non-small cell lung cancer compared to the current standard treatment, Tagrisso. This new treatment targets a resistance pathway, offering a potential lifeline for many patients, although it requires infusions and has potential side effects. Full trial results are forthcoming, and the company anticipates substantial sales. The development highlights advances in precision medicine for lung cancer.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    17 mins
  • #12: What You need to know about Ozempic and Weight Loss

    #12: What You need to know about Ozempic and Weight Loss
    Jan 9 2025
    This podcast episode discusses Ozempic (semaglutide), a GLP-1 receptor agonist initially used for type 2 diabetes, now gaining popularity for weight loss. The episode details its mechanism of action, effectiveness (showing up to 15% weight loss in trials but with caveats regarding individual responses and potential for weight regain), safety (including common and rare side effects), ethical considerations (addressing societal pressures and the need for holistic care), and cost (highlighting affordability issues and the need for equitable access). The podcast aims to inform healthcare professionals and the public about the drug's benefits, limitations, and broader implications.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    20 mins
  • #11: Interview with Derek Fetzer, Director- Regeneron Pharma

    #11: Interview with Derek Fetzer, Director- Regeneron Pharma
    Jan 8 2025
    This episode features an interview with Derek Fetzer, a corporate entrepreneur who successfully launched the Caring Crowd crowdfunding platform for global public health while working at Johnson & Johnson. Fetzer discusses his approach to intrapreneurship, emphasizing the importance of understanding organizational goals and pain points, building excitement through stealth innovation, and navigating internal stakeholders. He also shares insights on market research, advocating for a focused approach rather than a broad "boil the ocean" strategy, and highlights the significance of embracing failure as a learning opportunity and stresses the importance of aligning one's work with personal purpose.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    27 mins
  • #10: Interview with Dr Luis Taveras CIO Lehigh Valley Health Network

    #10: Interview with Dr Luis Taveras CIO Lehigh Valley Health Network
    Jan 8 2025
    This podcast features an interview with Dr.Luis Traves, a healthcare CIO, who recounts his experiences during the 9/11 terrorist attacks and how that shaped his approach to leadership. He discusses his evolving role as CIO, emphasizing the shift from a purely technical focus to a broader general management perspective. Dr. Luis Taveras also details his "90-Day CIO" model, a framework for achieving organizational success within the first 90 days of a leadership role, built on a value-based foundation. Finally, he shares his personal philosophy on self-management, balancing high-performance work with family life, underscoring the importance of authenticity, hard work, and strong family bonds.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    41 mins
  • #9: Interview with Nic Lamb- Founder, Ice Beanie

    #9: Interview with Nic Lamb- Founder, Ice Beanie
    Jan 8 2025
    This podcast features Nic Lamb, the founder of Ice Beanie, a company selling cold-therapy beanies for migraine relief. Nick recounts his entrepreneurial journey, from a $10,000 investment to a seven-figure business, including securing a deal with Mark Cuban on Shark Tank. The conversation also covers the challenges and rewards of his partnership with Cuban and the rigorous Shark Tank application process. Finally, Nic discusses his business philosophy, focusing on customer feedback, product innovation (including the Ice Beanie 2.0), omni-channel marketing strategies, and the importance of holistic health and wellness in achieving business success.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    27 mins
  • #8 : Lung Cancer Treatment Landscape

    #8 : Lung Cancer Treatment Landscape
    Jan 3 2025
    This podcast discusses the complexities of lung cancer treatment, highlighting its status as a leading cause of cancer deaths globally. The discussion emphasizes the disease's heterogeneity, including various subtypes and stages, impacting treatment strategies. Significant advancements in targeted therapies and immunotherapies are noted, offering more precise approaches compared to older methods. The importance of personalized medicine and biomarkers in tailoring treatments to individual patients is stressed. Finally, the podcast encourages collaboration and continued research to improve outcomes in this challenging field.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    5 mins
  • #7: The FDA Approves Zepbound for Sleep Apnea

    #7: The FDA Approves Zepbound for Sleep Apnea
    Dec 22 2024
    This podcast segment discusses the FDA approval of Zepbound, a novel injectable drug with a unique mechanism of action, representing a significant market disruption. The drug's innovative approach and potential for improved patient convenience are highlighted, alongside projections of substantial market share capture. However, the discussion also acknowledges potential challenges, including pricing and reimbursement hurdles, and the need for ongoing long-term safety and efficacy monitoring. Ultimately, the segment emphasizes the need for industry adaptability and reassessment of R&D strategies in response to this game-changing drug.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
    4 mins